Evidence map›Paper›PMID 23344789›Full record

SynthesisJournal of neuro-oncology2013

Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality?

Ashish H Shah, Brian Snelling, Amade Bregy, Payal R Patel, Danoushka Tememe, Rita Bhatia, Evelyn Sklar, Ricardo J Komotar

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Journal of neuro-oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 3 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 3 syntheses or guidelines pooled it, 103 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Diagnostic accuracy of [Neuroradiology · 2026
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Preclinical and Clinical Use of Indigenously DevelopedACS pharmacology & translational science · 2023
    Review
  12. Review
  13. Review
  14. Article
  15. Radiology · 2022
    Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. NegativeEuropean journal of hybrid imaging · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Ashish H ShahDepartment of Neurological Surgery, University of Miami, Miami, FL 33125, USA.
Brian Snelling
Amade Bregy
Payal R Patel
Danoushka Tememe
Rita Bhatia
Evelyn Sklar
Ricardo J Komotar
University of Miami · USNeurological Surgery · USNova Southeastern University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Differentiating post radiation necrosis from progression of glioma and pseudoprogression poses a diagnostic conundrum for many clinicians. As radiation therapy and temozolomide chemotherapy have become the mainstay of treatment for higher-grade gliomas, radiation necrosis and post treatment changes such as pseudoprogression have become a more relevant clinical problem for neurosurgeons and neurooncologists. Due to their radiological similarity to tumor progression, accurate recognition of these findings remains paramount given their vastly different treatment regimens and prognoses. However, no consensus has been reached on the optimal technique to discriminate between these two lesions. In order to clarify the types of imaging modalities for recurrent enhancing lesions, we conducted a systematic review of case reports, case series, and prospective studies to increase our current understanding of the imaging options for these common lesions and their efficacy. In particular, we were interested in distinguishing radiation necrosis from true tumor progression. A PubMed search was performed to include all relevant studies where the imaging was used to differentiate between radiation necrosis and recurrent gliomas with post-radiation enhancing lesions. After screening for certain parameters in our study, seventeen articles with 435 patients were included in our analysis including 10 retrospective and 7 prospective studies. The average time from the end of radiation therapy to the onset of a recurrent enhancing lesion was 13.2 months. The most sensitive and specific imaging modality was SPECT with a sensitivity of 87.6 % and specificity of 97.8 %. Based on our review, we conclude that certain imaging modalities may be preferred over other less sensitive/specific techniques. Overall, tests such as SPECT may be preferable in differentiating TP (tumor progression) from RN (radiation necrosis) due to its high specificity, while nonspecific imaging such as conventional MRI is not ideal.

Indexed as

Diagnostic ImagingBrain NeoplasmsDiagnosis, DifferentialDisease ProgressionGliomaHumansNecrosisRadiation Injuries

Identifiers

PMID23344789
OpenAlexW2011276562

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.